INT332620

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.08
First Reported 2010
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 1
Total Number 2
Disease Relevance 1.07
Pain Relevance 0.20

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

signal transduction (Glp1r) plasma membrane (Glp1r) signal transducer activity (Glp1r)
Anatomy Link Frequency
hypothalamus 2
Glp1r (Mus musculus)
Pain Link Frequency Relevance Heat
agonist 8 100.00 Very High Very High Very High
tolerance 14 73.52 Quite High
Paracetamol 2 71.92 Quite High
Inflammation 10 5.00 Very Low Very Low Very Low
pruritus 4 5.00 Very Low Very Low Very Low
headache 4 5.00 Very Low Very Low Very Low
cytokine 2 5.00 Very Low Very Low Very Low
fibrosis 2 5.00 Very Low Very Low Very Low
Neuropeptide 2 5.00 Very Low Very Low Very Low
abdominal pain 2 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Diabetes Mellitus 190 99.84 Very High Very High Very High
Body Weight 2 95.96 Very High Very High Very High
Overweight 4 87.84 High High
Hyperglycemia 22 68.60 Quite High
Hypoglycemia 58 55.16 Quite High
Gastric Motility Disorder 2 36.00 Quite Low
Insulin Resistance 32 5.00 Very Low Very Low Very Low
Obesity 20 5.00 Very Low Very Low Very Low
Atherosclerosis 20 5.00 Very Low Very Low Very Low
Heart Rate Under Development 18 5.00 Very Low Very Low Very Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
In animal models, the inhibitory effect on food intake is observed when GLP-1 is administered peripherally122 or intraventricularly.123,124 The inhibition of food intake by GLP-1 results from activation of GLP-1 receptors in the hypothalamus and the area postrema, which are accessible from the systemic circulation.125 A meta-analysis of seven human studies has demonstrated that GLP-1 administration reduces energy intake and increases satiety in lean and overweight subjects.126

Incretin formulations

Negative_regulation (inhibition) of Gene_expression (administered) of GLP-1 in hypothalamus associated with overweight
1) Confidence 0.08 Published 2010 Journal Vascular Health and Risk Management Section Body Doc Link PMC2941781 Disease Relevance 0.67 Pain Relevance 0.04
In a mechanism of action study, DeFronzo et al10 compared sitagliptin, a DPP-4 inhibitor, with exenatide, a GLP-1 agonist.
Negative_regulation (inhibitor) of Gene_expression (agonist) of GLP-1 associated with agonist
2) Confidence 0.08 Published 2010 Journal Vascular Health and Risk Management Section Body Doc Link PMC2941781 Disease Relevance 0.41 Pain Relevance 0.16

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox